We are live on ! Find out more
RLMD icon

Relmada Therapeutics
RLMD

44 hedge funds and large institutions have $1.68M invested in Relmada Therapeutics in 2025 Q1 according to their latest regulatory filings, with 8 funds opening new positions, 4 increasing their positions, 14 reducing their positions, and 12 closing their positions.

New
Increased
Maintained
Reduced
Closed

7.22% less ownership

Funds ownership: 27.84% → 20.61% (-7.2%)

8% less funds holding

Funds holding: 48 → 44 (-4)

33% less first-time investments, than exits

New positions opened: 8 | Existing positions closed: 12

62% less capital invested

Capital invested by funds: $4.36M → $1.68M (-$2.68M)

71% less repeat investments, than reductions

Existing positions increased: 4 | Existing positions reduced: 14

Holders
44
Holders Change
-4
Holders Change %
-8.33%
% of All Funds
0.59%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
8
Increased
4
Reduced
14
Closed
12
Calls
$20K
Puts
–
Net Calls
+$20K
Net Calls Change
-$189K

Top Buyers

1
Goldman Sachs
Goldman Sachs
New York
+$40.1K
2
Two Sigma Advisers
Two Sigma Advisers
New York
+$29.5K
3
AI
AdvisorShares Investments
Maryland
+$22K
4
HF
HRT Financial
New York
+$17.3K
5
Two Sigma Investments
Two Sigma Investments
New York
+$14.2K

Top Sellers

1
Franklin Resources
Franklin Resources
California
-$417K
2
TCM
Tang Capital Management
California
-$104K
3
Barclays
Barclays
United Kingdom
-$75.9K
4
GCP
GSA Capital Partners
United Kingdom
-$65K
5
Bank of America
Bank of America
North Carolina
-$64K
Name Holding Trade Value Shares
Change 		Change in
Stake
RSWM
26
Robertson Stephens Wealth Management
California
$6.75K – – –
TIM
27
Tortoise Investment Management
New York
$5.85K – – –
WIA
28
World Investment Advisors
California
$5.84K -$2.67K -8,040 -27%
PW
29
Pandora Wealth
Illinois
$5.4K +$6.63K +20,000 New
TSS
30
Two Sigma Securities
New York
$3.78K +$4.64K +14,012 New
Lido Advisors
31
Lido Advisors
California
$3.75K +$4.61K +13,905 New
Bank of America
32
Bank of America
North Carolina
$3.7K -$64K -192,941 -93%
SG
33
StoneX Group
New York
$3.57K +$4.39K +13,234 New
BFC
34
Bedel Financial Consulting
Indiana
$3.57K – – –
HCP
35
Hexagon Capital Partners
Arkansas
$1.08K – – –
ACA
36
American Capital Advisory
Idaho
$1.06K +$648 +1,954 +100%
Simplex Trading
37
Simplex Trading
Illinois
$1K +$1.49K +4,482 New
Morgan Stanley
38
Morgan Stanley
New York
$585 -$4.98K -15,029 -87%
JP Morgan Chase
39
JP Morgan Chase
New York
$43 -$12.4K -37,542 -100%
SS
40
SBI Securities
Japan
$28 – – –
BNP Paribas Financial Markets
41
BNP Paribas Financial Markets
France
$19 – – –
FRA
42
Front Row Advisors
California
$2 +$2 +6 New
Citigroup
43
Citigroup
New York
$1 -$20.9K -62,947 -100%
Osaic Holdings
44
Osaic Holdings
Arizona
$1 -$9 -27 -84%
TCM
45
Tang Capital Management
California
– -$104K -200,825 Closed
Barclays
46
Barclays
United Kingdom
– -$75.9K -145,999 Closed
GCP
47
GSA Capital Partners
United Kingdom
– -$65K -124,773 Closed
RA
48
Rosalind Advisors
Ontario, Canada
– -$52K -100,000 Closed
BCM
49
Bridgeway Capital Management
Texas
– -$37.8K -72,600 Closed
Jacobs Levy Equity Management
50
Jacobs Levy Equity Management
New Jersey
– -$23.7K -45,602 Closed
1
2
3

RLMD Hedge Fund Activity: Q1 2025 in Review

44 of the 7,457 institutional investors tracked by Wall St. Rank reported a position in Relmada Therapeutics (RLMD) for Q1 2025, worth a combined $1.68M — down 62% from $4.36M a quarter earlier.

Sellers outnumbered buyers: 12 funds closed out of RLMD and 8 opened new positions — a net loss of 4 holders — while 14 trimmed existing stakes and 4 added.

The largest buyer was Goldman Sachs, opening a new position worth an estimated $40.1K. The largest seller was Franklin Resources, cutting an estimated $417K.

  • 44 institutional investors held Relmada Therapeutics (RLMD) as of Q1 2025, down from 48 in Q4 2024.
  • Funds reported $1.68M of Relmada Therapeutics stock for Q1 2025, down 62% quarter-over-quarter.
  • 8 funds opened new Relmada Therapeutics positions in Q1 2025 and 12 closed out, a net change of -4 holders.
  • The largest Relmada Therapeutics buyer in Q1 2025 was Goldman Sachs, an estimated $40.1K added.
  • The largest Relmada Therapeutics seller in Q1 2025 was Franklin Resources, an estimated $417K sold.

Based on aggregated 13F filings for Q1 2025.